Title: Amyloid Reduction and Dementia Progression in Dominantly Inherited Alzheimer's Disease after Long-Term Gantenerumab Treatment: Results from the DIAN-TU Trial

Authors: Randall J. Bateman[1*], Yan Li[1#], Eric M. McDade[1], Jorge J. Llibre-Guerra[1], David B. Clifford[1], Alireza Atri[2], Susan L. Mills[1], Anna M. Santacruz[1], Guoqiao Wang[1], Charlene Supnet[1], Tammie L. S. Benzinger[1], Brian A. Gordon[1], Laura Ibanez[1], Gregory Klein[3], Monika Baudler[3], Rachelle S. Doody[3], Paul Delmar[3], Geoffrey A. Kerchner[3], Tobias Bittner[3], Jakub Wojtowicz[3], Azad Bonni[3], Paulo Fontoura[3], Carsten Hofmann[3], Luka Kulic[3], Jason Hassenstab[1], Andrew J. Aschenbrenner[1], Richard J. Perrin[1], Carlos Cruchaga[1], Alan E. Renton[4], Chengjie Xiong[1], Alison M. Goate[4], John C. Morris[1], David M. Holtzman[1], B. Joy Snider[1], Catherine Mummery[5], William S. Brooks[6], David Wallon[7], Sarah B. Berman[8], Erik Roberson[9], Colin L. Masters[10], Douglas R. Galasko[11], Suman Jayadev[12], Rachel Sanchez Valle[13], Jeremie Pariente[14] Justin Kinsella[15], Christopher H. van Dyck[16], Serge Gauthier[17], Ging-Yuek Robin Hsiung[18], Mario Masellis[19], Bruno Dubois[20], Lawrence S. Honig[21], Clifford R. Jack[22], Alisha Daniels[1], Ricardo Allegri[23], Jasmeer Chhatwal[24], Gregory Day[25], Nick Fox[5], Edward Huey[26], Takeshi Ikeuchi[27], Mathias Jucker[28], Jae-Hong Lee[29], Allan I. Levey[30], Johannes Levin[31], Francisco Lopera[32], JeeHoon Roh[29], Pedro Rosa-Neto[17], Peter R. Schofield[6] for the Dominantly Inherited Alzheimer's Disease-Trials Unit.

* Corresponding author: batemanr@wustl.edu
\# Co-corresponding biostatistics author: yanli833@wustl.edu

Affiliations:
1. Washington University School of Medicine, St. Louis, MO, USA
2. Banner Health, Phoenix, AZ, USA
3. F. Hoffmann-La Roche Ltd, Basel, Switzerland
4. Icahn School of Medicine Mt. Sinai, New York, NY, USA
5. University College London, United Kingdom
6. Neuroscience Research Australia, Sydney, NSW, Australia
7. Centre Hospitalier Universitaire de Rouen, Rouen, France
8. University of Pittsburgh Medical Center, Pittsburgh, PA, USA
9. University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
10. University of Melbourne, Melbourne, Victoria, Australia
11. University of California San Diego, San Diego, CA, USA
12. University of Washington School of Medicine, Seattle, WA, USA
13. Hospital Clínic i Provincial de Barcelona, August Pi i Sunyer Biomedical Research Institute-Universitat de Barcelona, Barcelona, Spain
14. Centre Hospitalier Universitaire de Toulouse, Toulouse, France
15. St Vincent's University Hospital, Ireland
16. Yale University School of Medicine, New Haven, CT, USA
17. McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
18. University of British Columbia, Vancouver, British Columbia, Canada
19. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
20. Neurological Institute, Salpetriere University Hospital, Paris, France
21. Columbia University Medical Center, New York, NY, USA
22. Mayo Clinic, Rochester, MN, USA
23. Instituto de Investigaciones Neurologicas Raul Carrea (Fleni), Buenos Aires, Argentina
24. Brigham and Women's Hospital, Boston, Massachusetts, USA
25. Mayo Clinic, Jacksonville, FL, USA
26. Butler Hospital, Providence, RI, USA

27. Niigata University, Niigata, Japan
28. German Center for Neurodegenerative Diseases (DZNE) Tuebingen, Germany
29. Asan Medical Center, Seoul, South Korea
30. Emory University, Atlanta, GA, USA
31. German Center for Neurodegenerative Diseases (DZNE) Munich, Germany
32. Universidad de Antioquia, Medellin, Colombia

Summary

Background: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease (AD), however the potential for delaying the onset of clinical symptoms in asymptomatic people are unknown. We conducted a trial of gantenerumab to evaluate whether amyloid-plaque removal delays symptom onset and AD progression in asymptomatic dominantly inherited AD (DIAD) individuals.

Methods: This double-blind, phase 2/3 trial, followed by open-label extension (OLE), investigated increasing gantenerumab doses up to 1500 mg subcutaneous every 2 weeks (NCT01760005). We report Interim and Final Analyses of clinical outcomes, amyloid-plaque removal, and biomarkers in asymptomatic mutation carriers treated for up to 10 years. The final primary endpoint was the change from OLE baseline to year 3 in PiB-PET SUVR. Key secondary endpoints were the time to recurrent progression of the Clinical Dementia Rating® (CDR) using the Cox proportional hazards model, compared to internal and external controls.

Findings: The primary outcome was positive with amyloid removal of 0.71 SUVR (95% CI 0.53 to 0.88, p< 0.0001). For the clinical decline of CDR-SB, in the group with any gantenerumab exposure (n=53, average dosing 4.3 years), the hazard ratio was 0.79 (0.48 to 1.29), while in the longest-treated group (n=22, average 8.4 years), the hazard ratio was 0.57 (0.31 to 1.07). CSF amyloid-beta 42/40 and p-tau181/tau181 improved proportionally with amyloid reduction. Amyloid-related imaging abnormalities occurred in 53% of participants: 47% with microhemorrhages, 30% with edema, and 6% were associated with symptoms. No treatment-associated macrohemorrhages or deaths occurred.

Interpretation: While the overall group did not show significant clinical effects, results suggest potential delayed symptom onset and dementia progression in asymptomatic DIAD individuals with long-term, high-dose gantenerumab exposure. Firm conclusions are limited due to the OLE design and use of external controls.

Funding: National Institutes on Aging**,** Alzheimer's Association, GHR, F. Hoffmann-La Roche, Ltd/Genentech

INTRODUCTION

Alzheimer's disease (AD) is a devastating neurodegenerative disorder with a growing global health burden. Decades of research support the amyloid hypothesis, which posits that cerebral accumulation of amyloid-beta (Aβ) plaques is a key initiating event in AD pathogenesis.[1,2] While amyloid-plaque lowering monoclonal antibody therapies, including aducanumab, lecanemab, and donanemab, demonstrate the amyloid-plaque removal and associated slowing of cognitive and functional decline at the group level in early symptomatic AD (mild cognitive impairment or mild AD dementia), their ability to prevent or delay the onset of cognitive impairment in at risk individuals is unknown.[3–5]

Dominantly inherited Alzheimer's disease (DIAD) is caused by autosomal dominant mutations in presenilin-1 (*PSEN1*), presenilin-2 (*PSEN2*), or the amyloid-beta precursor protein (*APP*) genes that alter APP processing, resulting in overproduction of aggregation prone Aβ and accumulation of Aβ-plaque pathology in early to mid-adulthood.[6–8] Carriers of these mutations have a predictable age of symptom onset and follow a preclinical stage characterized by Aβ-plaque deposition decades before cognitive decline, providing a unique model for investigating disease-modifying therapies in a prevention paradigm.[9]

In 2012, the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) launched a pioneering prevention trial (DIAN-TU-001, NCT01760005) to investigate the efficacy of two anti-amyloid monoclonal antibodies (solanezumab and gantenerumab) in delaying symptom onset and slowing progression in asymptomatic and mildly symptomatic DIAD mutation carriers. While the double-blind period of the DIAN-TU-001 phase 3 trial (2012-2019) with gantenerumab did not meet its primary endpoint of slowing cognitive decline in both symptomatic and asymptomatic cohorts, it demonstrated significant but incomplete reduction of amyloid-plaques in a dose-dependent fashion, reduction of cerebrospinal fluid (CSF) total tau and tau phosphorylated at threonine 181 (p-tau181), and attenuation of CSF neurofilament light chain, a non-specific marker of neurodegeneration, particularly in asymptomatic DIAD mutation carriers.[10] Further examination of downstream CSF and blood-based biomarkers showed that gantenerumab treatment significantly improved multiple CSF measures of synaptic degeneration, microglial activity, other inflammatory markers and astrocyte activation markers.[11] Together, these data provided the rationale to continue with a 3-year open-label extension study (OLE, 2020-2023, NCT06424236), with the goal of determining if continued treatment with gantenerumab at substantially higher doses than those used in sporadic AD (SAD) studies and the DIAN-TU double-blind period could result in complete removal of brain amyloid plaques, improve critical markers of disease progression, improve or normalize non-amyloid related downstream biomarkers, and impact expected clinical and cognitive measures and trajectories.

The GRADUATE I and II trials of gantenerumab in symptomatic SAD did not demonstrate significant slowing of clinical decline.[12] This outcome could be attributed to the fact that the magnitude of amyloid plaque removal was smaller than predicted, with only one quarter of participants treated with gantenerumab reaching amyloid negative status at the end of the trial.[12] As the DIAN-TU gantenerumab OLE was ongoing when the GRADUATE results were reported, and the cohort had been treated for approximately 8 years at that time, we established a pre-specified interim analysis to determine whether substantial clinical benefit of slowed disease progression and amyloid removal was achieved and whether continuation to complete the study was justified. Here we report the interim and final results from the DIAN–TU-001 gantenerumab OLE trial for the pre-specified primary and secondary outcomes.

METHODS

Study design

The DIAN-TU-001 was a randomized (with minimization procedure), double-blind, placebo-controlled, phase 2/3 trial of solanezumab and gantenerumab with a common close design conducted from December 2012 to November 2019.[10] Allocation concealment was performed. Briefly, the DIAN-TU-001 was a two-year biomarker study that was transitioned to a four-year treatment trial with a cognitive primary end point to investigate the potential for amyloid-removing drugs to slow or prevent cognitive decline. This gantenerumab OLE was designed to continue to treat eligible participants from the DIAN-TU-001 double-blind period with substantially increasing high doses of gantenerumab for 3 years. There was an average treatment gap of approximately 1 year (0.4 SD) between the end of the double-blind period and the start of the OLE period in 2020 (Figure 1A). Recruitment took place between June 03, 2020 and April 22, 2021 at 18 DIAN-TU study sites in the continental United States of America (US), Puerto Rico, Spain, United Kingdom, Ireland, Canada, Australia, and France. The study included a pre-specified interim analysis involving selected clinical, cognitive and biomarker endpoints to determine: (i) if high-dose and/or long-term gantenerumab treatment resulted in clinical benefit, and (ii) whether the high doses of gantenerumab resulted in substantial amyloid removal compared to the double-blind period. The interim analysis was conducted when most participants had received 2 years of high dose gantenerumab treatment (data lock March 31, 2023). Due to the lack of a conclusive major clinical benefit and regulatory path for gantenerumab, dosing was stopped in August 2023 and the study was closed by the sponsor.

Ethics approval was obtained through a central Institutional Review Board (Advarra) for US sites. Ethics committee approval was obtained at all other participating sites.

Participants

Seventy-four DIAD mutation carriers who participated in the double-blind period of the DIAN-TU-001 trial were enrolled in the OLE. Participants were between 15 years before to 10 years after (inclusive) of their estimated years to symptom onset (EYO = participant's age at the clinical assessment – participant's mutation and parental estimated age at symptom onset),[19] had a Clinical Dementia Rating® (CDR®) global score of 0 (cognitively normal) to 1 (mild dementia), and were willing to know their mutation status (a requirement to participate in the OLE). Participant mutation status and *APOE* genotype were determined using Clinical Laboratory Improvement Amendments (CLIA) whole exome sequencing. The main exclusion criteria included major or unstable illness that would prevent trial participation or completion of main study-related testing, volumetric magnetic resonance imaging (MRI) contraindications, required anticoagulation therapy, or pregnancy. Other reasons for exclusion included advanced disease, death, or early termination from the double-blind period for other reasons. A small number were unwilling to know their mutation status and declined participation. For recruitment flow of participants from the double-blind period to OLE, see Figure 1A.

Participant data with a cutoff date of June 30, 2022 from the DIAN Observational study (DIAN Obs, NCT00869817)[9,20] and met the DIAN-TU-001 trial inclusion criteria were used as natural history external controls. DIAN Obs participant mutation status was determined using Sanger sequencing (single nucleotide variant and indel mutations) or TaqMan genotyping (copy number variant mutations), and *APOE* genotype was determined using TaqMan. Internal controls are

the data from placebo treated participants from the double-blind who did not enroll in OLE period. Of note, the DIAN Obs and DIAN-TU studies are harmonized with close protocols, including use of the same clinical, cognitive, imaging, and biomarker measures. Participant groups for analysis included the main set of controls, defined as the external controls (DIAN Obs) plus the internal controls (placebo treated in the double-blind) (Figure 1B-D). The extended set controls (dashed box on Figure 1C) are defined as the main set controls plus the double-blind baseline and OLE baseline values for participants treated with placebo during the double-blind period and entered the OLE.

Procedures

Dosing

During the double-blind period, participants received increasing doses of gantenerumab (Generation 3 drug product), from 225 mg and up to 1200 mg subcutaneous (SC) administration every 4 weeks, or placebo. During the OLE phase, gantenerumab (Generation 4 drug product used in the GRADUATE trials) doses were titrated from 120mg every 4 weeks to up to 1020 or 1500 mg every 2 weeks (see Supplemental Figure 1 for dose titration schedule). The 1020 mg Generation 4 dose was PK-equivalent of the 1200 mg Generation 3 dose. The average titration time to the highest doses was 19 months, with 57/73 (78%) participants completing titration to the highest dose. The planned duration of treatment in the OLE was 3 years. To reduce participant burden, home health nurses were utilized for most drug administration visits.

Assessments

Clinical and cognitive assessments were performed at baseline and every 6 months. These included CDR global and Sum-of-Box scores (CDR-SB), Functional Assessment Scale (FAS), Mini-Mental State Examination (MMSE), and the DIAN-TU OLE Cognitive Composite (consisting of 4 components: the Wechsler Memory Scale-Revised Digit Span Backward Recall, the Category Fluency (Animals) total correct score, the Wechsler Adult Intelligence Scale Digit Symbol Substitution Test total correct score, and the total score from the MMSE, Supplemental Methods 2). Blood collection for serum and/or plasma was performed every 6 months. Volumetric MRI (vMRI), ^{11}C-Pittsburgh compound-B positron emission tomography (PiB-PET), flortaucipir (Tauvid®) PET (Tau-PET) and lumbar puncture for CSF collection were conducted annually. In addition to the annual vMRIs, safety surveillance MRIs for amyloid-related imaging abnormalities (ARIA)[21] monitoring were collected at 9 weeks, then every 12 weeks thereafter. Safety follow-up visits were performed 12 weeks after the last dose of gantenerumab. Safety assessments included adverse events, pregnancy testing and vitals at each dosing visit, and routine laboratory assessments and physical examinations every 6 months.

Imaging methods

Structural MRI was performed using the Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol using 3T MRI scanners. The ADNI Imaging Core screened images for protocol compliance, artifacts and ARIA. T1-weighted images (1.1 × 1.1 × 1.2 mm voxels) were acquired for all participants as to perform volumetric quantification. The presence and number of cerebral microbleeds and siderosis was evaluated on gradient echo images (GRE, 0.86 x 0.86 x 4 mm voxels). ARIA-E was evaluated on FLAIR images (0.86 x 0.86 x 5.0 mm voxels).

Regions of interest (ROIs) were defined by FreeSurfer on the MRI scans were used for the regional processing of all PET data. PiB-PET data from the 40–70-min postinjection window were converted to regional standard uptake value ratios (SUVRs) relative to the cerebellar gray matter (https://github.com/ysu001/PUP). A composite to represent a global measure of Aβ-plaques was calculated using the averaged SUVR values in the precuneus, caudate, gyrus rectus, occipital cortex, parietal cortex, prefrontal cortex and temporal cortex regions. The Tau-PET summary region is the average SUVR values for the postcentral gyrus, supramarginal gyrus, superior parietal cortex, inferior parietal cortex, precuneus, posterior cingulate, and isthmus cingulate. Both types of PET data were partial volume-corrected using a regional spread function technique.[22]

Fluid biomarker methods

Cerebrospinal fluid was collected at DIAN-TU sites under fasting conditions using a 22-G atraumatic Sprotte spinal needle (except when fluoroscopy was required) into a single 50 mL polypropylene tube via gravity drip methods. The fluid was immediately processed into 10 0.5 mL aliquots in 2.0 mL polypropylene tubes and flash frozen. The tubes were shipped overnight on dry ice to the central laboratory (LabCorp) for storage at −80 °C. Samples were shipped to the DIAN-TU Biomarker Core laboratory at Washington University, St. Louis, Missouri for analysis. All tubes were stored at −80 °C.

One freeze-thaw cycle CSF aliquots were used for the analysis of Aβ1-40, Aβ1-42, and p-tau concentrations measured using high-precision immunoprecipitation-coupled mass spectrometry (IP-MS) as previously described.[23,24]

Outcomes

The pre-specified primary objective of the final analysis of the OLE is to determine if gantenerumab at the target high dose would result in removal of brain amyloid plaque relative to OLE baseline after 3 years of treatment. The primary outcome measure was the change in amount of amyloid-plaque deposition as measured by the PiB-PET composite.

The key secondary outcome was CDR global and CDR-SB progression. CDR stages dementia severity by assessing six domains: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. A CDR global score of 0 represents normal or no cognitive impairment, 0.5 very mild, 1 mild, 2 moderate and 3 severe dementia. Time to first progression in CDR global is defined as the time from OLE baseline to the first visit where CDR increases. Progression must be observed at two consecutive measurements unless progression occurs at the final measurement. CDR-SB is an 18-point ordinal measure of dementia severity, with higher scores representing greater severity. Recurrent progression of CDR-SB is any progression which is either the first increase in value above baseline or any progression above the highest preceding post-baseline value identified as a progression, where progression above the preceding value must be observed at two consecutive measurements unless the progression occurs at the last measurement. For example, if a participant's CDR-SB is 0, 0.5, 0.5 and 1 at baseline, year 1, 2 and 3, respectively, then this participant had two progressions: 0 to 0.5 from baseline to year 1, and 0.5 to 1 from year 2 to 3. Event time is defined as time since baseline for the first progression and time to previous event for subsequent progressions. Participants without a progression event at their last measurement

were censored at the time of that measurement.

Other secondary endpoints included: (i) DIAN-TU Cognitive Composite (Supplemental Method 2), with lower scores interpreted as worse performance; (ii) FAS, which measures the participant's ability to perform daily activities, with higher scores indicating worse performance; (iii) MMSE with lower scores indicate worse performance. For FAS and MMSE, increases of 3 units or more was considered a progression and time to recurrent progression was defined similarly as CDR-SB. (iv) Biomarkers CSF Ab 1-42/1-40, with lower values indicating abnormality; and Tau-PET SUVR and CSF p-tau181/tau181, with higher values indicating abnormality. (v) CSF neurofilament light chain (NfL) analysis is in progress and will be reported once available.

Key outcomes used for interim analysis are detailed in Supplemental Methods 3. The pre-specified primary endpoints for the interim analysis were time to recurrent progression in CDR SB and time to first progression in CDR global.

Safety

Safety outcomes included the incidence and severity of treatment-emergent adverse events, serious adverse events (SAEs), and treatment discontinuations. Analyses were pre-specified to be on an intent-to-treat basis. Clinical laboratory evaluations, vital signs, and 12-lead electrocardiograms were also measured throughout the study. ARIA was a safety endpoint in this study. Surveillance MRI was built into the dose escalation design to monitor for ARIA events routinely, and any suspected ARIA was assessed by the medical monitoring team promptly (see Supplemental Figure 1).

These endpoints were developed and finalized by the DIAN-TU, Roche, and the U.S. Food and Drug Administration (FDA), and pre-specified in the Statistical Analysis Plan.

Statistical Analysis

Power Calculations

The OLE study successfully enrolled 74 participants and dosed 73 (1 participant screen failed). We estimated annual dropout rates of 5% and 10% and anticipated approximately 56 to 43 participants to remain at the end of the 3-year OLE. The power estimation was based on the primary efficacy endpoint of the change from OLE baseline to the end of the OLE period. Based on the gantenerumab treatment effect observed during double blind period,[10] the mean (SD) change from OLE baseline in PiB-PET SUVR was projected to be at least -0.47 (0.54) over the 3-year OLE period, with dosing up to 1500 mg every 2 weeks (Supplemental Method 4). Given the anticipated sample size, the study was predicted to have over 99% power to detect the projected mean change from baseline using a one-sided one-sample t-test with a type I error rate of 3%. One-sided test was used since double-blind period data already demonstrated gantenerumab can significantly reduce PiB-PET SUVR from baseline.

Statistical Approach

The primary analysis was performed for the OLE modified intent-to-treat (mITT) population, defined as participants who received any gantenerumab treatment post-OLE baseline, had at least one PiB-PET SUVR assessment prior to gantenerumab treatment and a post-baseline assessment (based on OLE period data only, referred to as "OLE only Gant", Figure 1D). All 73 participants enrolled in the OLE received gantenerumab treatment. The primary analysis of the primary endpoint of PiB-PET SUVR reduction from baseline in the OLE mITT population was performed using a mixed model for repeated measures (MMRM) analysis without controls. The MMRM included the OLE baseline PiB-PET SUVR and visit (treated as categorical) as fixed effects. An unstructured variance-covariance matrix was used to model the within-subject errors among the repeated measures. To demonstrate that gantenerumab significantly removes amyloid plaque at year 3, the upper bound of the 95% confidence interval at the year 3 OLE visit would be less than 0. To evaluate the treatment effect of gantenerumab during the whole study duration, the change from double-blind baseline to the end of the OLE period in PiB-PET SUVR by the double-blind treatment group was also evaluated using a similar MMRM model with fixed effects of double-blind baseline PiB-PET SUVR, visit, double-blind treatment group and its interaction with visit. The proportion of participants who converted from abnormal (PiB-PET SUVR > 1.25) to normal (PiB-PET SUVR ≤ 1.25) was also examined. The DIAN normal cutoff was 1.25 PiB-PET SUVR derived based on the 95th percentile of PiB-PET SUVR from asymptomatic non-carriers.

The primary analysis for the key secondary endpoint of time to recurrent progression in CDR-SB, involved comparing participants who were treated with gantenerumab in either the double-blind or OLE period (referred to as "Any Gant", Figure 1B) to the main set controls. For all the comparisons using the Cox model stated below, start time was the baseline for the corresponding population as defined in Figure 1B-D end time was the last available CDR assessment time. To compare the probability of recurrent progression in CDR-SB between treated and controls, the Cox proportional hazards model was applied employing the Andersen-Gill method,[13] a robust variance estimator to account for the correlation between recurrent events. The Cox model incorporated the group variable and baseline EYO as fixed effects in the analysis. Additionally, the Cox model was utilized to analyze the time to first progression in CDR Global. The Cox proportional hazards model generates hazard ratios that provide an estimate of the relative risk of progression between treatment and control groups. A hazard ratio of <1 indicates treatment group has lower risk of progression than control group and vice versa. For example, a hazard ratio of 0.50 would represent a 50% reduction in the risk of progression in the treatment group compared to the control group. The same Cox proportional hazard models were also applied to the comparison (i) between the longest gantenerumab mITT Population ("Longest Gant", Figure 1C) and the main set of controls, (ii) between Longest Gant mITT Population and the extended set of controls, (iii) between OLE only Gant mITT Population and the main set of control. Sensitivity analyses based on CDR are described in Supplemental Method 1. As post-hoc analysis, similar Cox models were also applied to the FAS and MMSE to estimate the hazard ratios between Longest Gant mITT Population and the extended set of control.

MMRM models similar to those used for PiB-PET SUVR were employed to analyze the key secondary endpoints CSF p-tau181/tau181 and CSF Aβ 1-42/1-40. The Linear Mixed Effects (LME) model with random intercept and random slope was utilized to analyze other key secondary endpoints including the Cognitive Composite, Functional Assessment Scale, MMSE and Tau-PET SUVR. For the LME analysis, the annual rate of change between the OLE mITT population and the main set controls (internal controls only for Tau-PET SUVR) was compared. The LME model incorporated time since baseline (treated as a continuous variable), treatment

group, the interaction between treatment group and time as fixed effects, and random intercepts and slopes for each participant as random effects. Unstructured covariance matrix was used for random effects. CSF biomarkers were also converted to CentiMarker values utilizing a similar methodology as the Centiloid conversion approach. For CentiMarker calculations, more abnormal biomarker raw values indicate worse disease stages as defined by the direction of disease vs. normal groups. The detailed steps for calculating CentiMarker are described in Supplemental Method 5.

For the interim analysis, the same MMRM and Cox models as described for the final analysis were used for amyloid PET SUVR, CDR SB and global.

All analyses were conducted using SAS software, version 9.4.

The safety analysis population includes all participants who received at least one dose of study drug in the gantenerumab OLE period. A Data Safety Monitoring Board (DSMB) reviewed unblinded safety monitoring data throughout the trial, assessed risk-benefit ratio acceptability, provided periodic recommendations regarding the progress of the study, and reported to the central Institutional Review Board and participant site Ethics Committees. The OLE is registered in ClinicalTrials.gov, NCT06424236.

Role of the funding source

The National Institutes on Aging, Alzheimer's Association and GHR had no role in study design, data collection, data analysis, data interpretation, or writing of the report. F. Hoffmann-La Roche, Ltd/Genentech was a collaborator on the study design, data analysis and data interpretation, and are co-authors of this report.

RESULTS

Participant characteristics

Of the 144 mutation carriers enrolled in the DIAN-TU-001 double-blind study, 74 (52%) were successfully recruited into the gantenerumab OLE study between June 03, 2020 and April 22, 2021; 21 (15%) declined participation, and 47 (33%) were ineligible to participate (Figure 1). One participant screen failed. The remaining 73 participants received gantenerumab treatment per protocol. Overall, 13 (18%) of these 73 participants completed the 3 years of treatment for the study; 47 (64%) stopped dosing due to early termination of the study by sponsor, and 13 (18%) prematurely discontinued the study for other reasons (Figure 1A). The primary analysis population for PiB-PET SUVR included 55 mITT participants in gantenerumab OLE. The mean duration of the OLE period was 2.4 years (range 0.86 to 3.01 years). For CDR analysis based on baseline asymptomatic participants (double-blind baseline for prior gantenerumab treated group and OLE baseline for prior placebo and solanezumab treated group), the Any Gant mITT population (Figure 1B) included 53 participants, the Longest Gant treated mITT population (Figure 1C) included 22 participants, the OLE only Gant treated mITT population included 40 participants (Figure 1D), the main set of control group included 74 participants, and the extended control group (Figure 1C) that included the OLE baseline measures, comprised 86 participants. Demographics and baseline characteristics at OLE or double-blind baseline are presented in Table 1. Length of follow up for different groups are presented in Supplemental

Table 1.

Interim Analysis primary and secondary outcomes: clinical dementia progression and amyloid plaque removal

We conducted a pre-specified interim analysis with the data collected up to March 31, 2023, when most participants had completed 2 years of treatment in OLE. The primary outcomes for asymptomatic participants who received Any Gant (n = 53) had a hazard ratio (95% CI) of 0.91 (0.43, 1.94) for time to first progression in CDR global, and 0.79 (0.47, 1.32) for time to recurrent progression in CDR-SB compared to the main set control. For the Longest Gant treated baseline asymptomatic group (n = 22) with average duration of 8 years, the hazard ratio (95% CI) was 0.43 (0.15, 1.26) for CDR global and 0.53 (0.27, 1.03) for CDR-SB. For the OLE period, the OLE only Gant baseline asymptomatic group with average duration of 2 years (n=40), the hazard ratio (95% CI) was 1.39 (0.46, 4.19) for CDR global and 1.41 (0.59, 3.33) for CDR-SB (see Supplemental Table 2). Thus, the study met the Interim Analysis primary endpoint in the longest treated group only. Amyloid-plaque removal, measured by PiB-PET SUVR, was dose-dependent, with approximately 3-fold greater rates of amyloid-plaque lowering by tripling the dose used in the double-blind period. However, only 8% of participants converted from amyloid abnormal to normal and 12% of participants stayed amyloid normal (defined by SUVR<1.25).

Final Analysis Primary efficacy endpoint: amyloid plaque removal

To determine if gantenerumab at high doses would result in the removal of brain amyloid, participants underwent PiB-PET at OLE baseline and after three years of gantenerumab treatment. Gantenerumab resulted in dose-dependent amyloid plaque removal (Table 2). The adjusted mean change from OLE baseline (mean 2.62) to year 3 was PiB-PET SUVR of -0.71 (95% CI -0.88 to -0.53, p < 0.0001). Significant reductions were also observed in PiB-PET SUVR from OLE baseline to the end of OLE year 1 (-0.12, 95% CI -0.21 to -0.03, p = 0.012) and OLE year 2 (-0.47, 95% CI -0.60 to -0.33, p<0.0001) (Figure 2A). Participants who received higher doses of gantenerumab (1020-1500 mg every 2 weeks) showed approximately 3-fold greater rates of amyloid plaque lowering, with annual reduction of 0.35 SUVR (OLE year 1 to 2) compared to those on lower doses (225 mg every 4 weeks), with annual reduction of 0.06 SUVR (Supplemental Figure 2). At the end of the OLE, 8 (15%) participants remained amyloid PET normal (defined by SUVR<1.25)[14], 8 (15%) participants converted from abnormal to normal, and 38 (70%) participants remained amyloid PET abnormal (Supplemental Table 8). In comparison, the group that was treated with gantenerumab the longest achieved 45% amyloid plaque negative (normal) status, with 55% remaining amyloid PET abnormal. Thus, the study met the Final Analysis primary endpoint.

At OLE year 3, a significant reduction in mean SUVR relative to the double-blind baseline was demonstrated for OLE participants from the gantenerumab treated arm (-0.44, 95% CI -0.76 to -0.12) and solanezumab treated arm (-0.47, 95% CI -0.86, -0.09), but not for OLE participants from the placebo arm (-0.07, 95% CI -0.51, 0.36) (Supplemental Figure 3).

Final Analysis Secondary outcomes: key clinical dementia progression

The interim analyses suggested that there may be delayed onset of symptoms and delayed dementia progression in DIAD mutation carriers who received long-term high-dose gantenerumab treatment before symptom onset. The pre-specified final analyses for CDR aim

to examine the impact of treatment duration on clinical outcomes, and to perform sensitivity analyses for clinical effects. To evaluate the time to first progression in CDR global and time to recurrent progression in CDR-SB, the pre-specified cohort of participants ever exposed to gantenerumab during the double-blind or the OLE periods (Any Gant, Figure 1B) was compared to the main set controls. In 53 participants who were asymptomatic at baseline and were included in Any Gant, the hazard ratio (95% CI) of time to first progression in CDR global score for treatment group vs. the main set of control was 0.84 (0.40 to 1.77), and the hazard ratio for time to recurrent progression in CDR-SB was 0.79 (0.48 to 1.29) (Figure 3, Supplemental Table 3).

To evaluate the population treated the longest with gantenerumab, a second pre-specified cohort of participants who started treatment during the double-blind and entered the OLE (Longest Gant, see Figure 1C) was compared to controls. For the subset of baseline asymptomatic participants with the Longest Gant treatment (n=22, average 8.44 years), the hazard ratio (95% CI) of time to first progression in CDR global for treatment group (n=22) compared to the main set of controls (n=74) was 0.41 (0.14 to 1.20); that for time to recurrent progression in CDR-SB was 0.57 (0.31 to 1.07). When comparing the treatment group with the extended control group (n = 86), the hazard ratio (95% CI) is 0.40 (0.14 to 1.16) for time to first progression in CDR global and 0.53 (0.29 to 0.97) for time to recurrent progression in CDR-SB (Figure 3, Supplemental Table 3). For each population, the number and percentage of censored participants and reasons for censoring are presented in Supplemental Table 4. Sensitivity analyses conducted either by excluding double-blind placebo arm participants who did not enroll in OLE from the main set of control or by using control participants matched by baseline EYO, length of follow-up and mutation type, resulted in similar hazard ratios (Supplemental Table 5).

To evaluate the population treated only during the OLE period with the highest doses of gantenerumab, a third cohort (OLE only Gant, Figure 1D) was analyzed. For the OLE baseline asymptomatic group and the OLE period data only, the hazard ratio (95% CI) of time to first progression in CDR global for treatment group (n = 40) compared to the main set of control (n=74) was 0.93 (0.33 to 2.58) and 1.32 (0.64, 2.70), respectively, for time to recurrent progression in CDR-SB.

Other secondary outcomes: cognitive and biomarker

The Functional Assessment Scale, MMSE and OLE cognitive composite outcomes showed no significant differences in the annual rate of change between the gantenerumab treated group (OLE period data only) and the main set of controls for either the OLE baseline asymptomatic group or baseline symptomatic group (Table 3). Post-hoc analyses of recurrent progression in FAS and MMSE for baseline asymptomatic participants with the Longest Gant treatment compared to the extended set control showed the hazard ratio was 0.59 (95% CI 0.22 to 1.58, p=0.29) for FAS and 0.54 (95% CI 0.21 to 1.39, p=0.20) for MMSE.

Gantenerumab treatment during the OLE period significantly improved CSF Aβ 1-42/1-40 (mean change from OLE baseline at year 3 in CentiMarker: -42; 95% CI, -52 to -31 , p<0.0001) and improved CSF p-tau181/tau181 (mean change from OLE baseline at year 3 in CentiMarker: -21; 95% CI, -25 to -17, p<0.0001) (Table 2 and Figure 2B,C). Change from baseline in original scale were provided in Supplemental Table 9.

No significant differences in the annual rate of change of Tau-PET SUVR were observed

between the treatment group (OLE period only) and the internal control group for either the OLE baseline asymptomatic group or the symptomatic group (Table 2).

Safety

The safety profile of gantenerumab at doses up to 1500 mg every 2 weeks was consistent with that observed during the double-blind period[15] and in other trials in SAD populations.[12] However, the ARIA-E rate was approximately one-third higher in the OLE compared to the rate observed with the lower doses in the double-blind period. Table 3 and Supplemental Table 6 summarizes the incidence of adverse events (AEs), which were greater than 10% in the OLE period. The most common AEs were infusion-related reactions (70%), upper respiratory tract infections (59%), and upper respiratory symptoms (45%).

During the OLE period, the incidence of ARIA-cerebral edema/effusion (ARIA-E) was 30% (n=22/73). Among those receiving higher doses (≥1020 mg every 2 weeks), the incidence of ARIA-E was 28% (n=17/60). Additionally, eight out of 22 participants experienced recurrent ARIA-E, totaling 32 episodes. Most ARIA-E episodes occurred within the first 4.7 months of receiving the higher doses. MRI analyses show that most ARIA-E events were multifocal, had a predominant occipital distribution, and a mean resolution time of 59.5 days. ARIA-E episodes were primarily asymptomatic (26/32). Symptomatic cases exhibited mild symptoms such as headache or transient disorientation. Symptomatic ARIA-E leading to hospitalization (worsening headaches and cortical blindness) occurred in two participants and both resolved with drug discontinuation. The frequency of ARIA-E was higher among *APOE* ε4 homozygous participants (2/3) compared to heterozygous participants (26%, 5/19) or non-carriers (29%,15/51). No cerebral macrohemorrhages were observed. No deaths were attributed to ARIA events.

DISCUSSION

The amyloid hypothesis of AD pathophysiology predicts that removal of cerebral amyloid should prevent or delay the onset of dementia or slow cognitive-behavioral decline. Clinical trials in DIAD presents an opportunity to test the hypothesis by initiating therapy in persons with brain amyloid deposits prior to symptom onset. The DIAN-TU-001 double-blind and OLE trials provide the longest test of this approach, and results suggest that removal of brain amyloid plaque relative to OLE baseline after 3 years of treatment is associated with delay in symptom onset. Favorable effects on AD biomarkers, such as Aβ 42/40 and p-tau181 suggest a delay in disease onset. While the hazard ratio of both Any Gant mITT population and OLE only Gant mITT population did not reach statistical significance, and no significant treatment effect was observed in the cognitive composite, MMSE and FAS for those treated for only 2-3 years, the outcomes from the longest-treated group (average of 8.4 years of exposure) suggest a possible benefit. The magnitude of effect of an approximately 50% slowing of dementia progression in the longest treated group is supported by multiple sensitivity analyses matching external and internal controls, the high predictability of disease onset and progression in DIAD mutation carriers, the large effect size point-estimate, similar magnitudes of effect on other clinical measures such as the FAS and MMSE, and the robustness of the CDR as a clinical measure of cognition and function. Further, ad-hoc analysis of the baseline asymptomatic gantenerumab arm double-blind period only, demonstrated a similar, but not significant, 49% slowing in the recurrent progression of CDR-SB compared to baseline asymptomatic placebo arm. These preliminary findings should be confirmed with continued long-term follow-up and treatment of this unique cohort.

Even though the hazard ratios (HR) for CDR global, FAS and MMSE were not statistically significant, the magnitude of the HRs are similar to HRs based on CDR-SB. For CDR global, only the first progression was considered and therefore it is less powerful than the recurrent progression for CDR SB. The negative findings of the Any Gant and OLE cohorts in CDR, cognitive composite, MMSE and FAS based on OLE only period data could be due to double-blind solanezumab and placebo treated participants having only been treated for 2~3 years of gantenerumab without sufficient amyloid plaque removal to normal levels yet. Due to limited sample size in this rare disease population, interpretation of the results should focus on the magnitude of the effect sizes and 95% CI, instead of statistical significance.

In the presence of amyloid removal therapy, we observed how the established biomarkers CSF Aβ 42/40 ratio and p-tau181 improved, approaching or even reaching the values considered normal in control groups. This finding supports the potential benefits of amyloid removal in this presymptomatic population, especially to prevent or mitigate the onset and progression of symptoms. In this trial, biomarker levels reached normal levels in asymptomatic participants, including in some individuals who were past their EYO, with a rate of biomarker change directly proportional to dosage, suggesting a potential dose-dependent effect, with a hypothetical plateau in the biomarker improvement towards normality when all plaques are removed. There was no significant treatment effect on tau PET in the overall group, similar to observations in SAD. However, future comparisons of the amount of tau pathology between the longest treated and control groups are underway.

The safety of anti-amyloid monoclonal therapy in early-stage symptomatic clinical AD (MCI and mild AD dementia) has been assessed in the context of restricted patient selection (e.g. microhemorrhages <5 with durations of only a few years). The participants in the DIAN-TU-001 trial have experienced the longest exposures to, and highest dosages of, gantenerumab administered to date, providing invaluable safety experience. Safety data from the DIAN-TU-001 OLE study indicate that tripling the dose of gantenerumab is reasonably well tolerated in DIAD populations, with the incidence and severity of adverse events remaining comparable to sporadic AD populations. However, higher doses in the OLE resulted in a third higher incidence than the double-blind period.[10] Development of spontaneous ARIA with haemosiderosis or microhemorrhage (ARIA-H) and a potentially associated increasing risk of ARIA-E has been noted in this DIAD population, with ARIA most often seen in symptomatic participants or those nearing their mutation EYO. As trials are implemented in asymptomatic participants to treat earlier phases of amyloid plaque deposition or for the primary prevention of plaques, it will be important to learn the degree of risk for ARIA events associated with these earlier regimens. Our experience to date is consistent with reduced risk at earlier stages of amyloid pathology. Most ARIA events were not associated with clinical symptoms. Careful MRI monitoring—particularly in the early stages of anti-amyloid treatment—allowed therapy to proceed without evidence of lasting impairment caused by ARIA. Additionally, the higher doses of gantenerumab were not associated with new or unexpected safety findings. These safety results were obtained by using a slow dose escalation that also reduced the reaching and duration of exposure to full doses of gantenerumab, but may have allowed early detection and management strategies to closely assess (radiologically and clinically) and to mitigate progression and clinical impact of ARIA-E. This approach could have mitigated the severity and impact of ARIA, contributing to the relatively low number of symptomatic cases and ensuring that episodes were fully reversible. Alternatively, the slow titration may not have had an impact on the rate of ARIA, or ARIA

detection, management, and safety outcomes.

Risks for ARIA-E in DIAD parallel those reported for gantenerumab in SAD, including increased risk of ARIA-E with *APOE* ε4 status and number of microhemorrhages.[12] Observed ARIA-E rates were comparable to the TRAILBLAZER-ALZ2 and GRADUATE trials (~25%) with gantenerumab in SAD. However, rates were higher than the 12% reported in the CLARITY AD trial of lecanemab in SAD. The higher ARIA-H relative to the double-blind period likely results from the combined effect of higher doses and disease progression. Previous DIAN Obs natural history studies have shown increased number and frequency of microhemorrhages with disease progression.[16] Thus, the natural increase in vascular amyloid due to disease progression, combined with higher amyloid-modifying therapies doses, contributes significantly to the increased ARIA-H incidence during the OLE phase.

These results are encouraging but limited by the long asymptomatic phase of the disease, the incomplete removal of amyloid with gantenerumab, limited participant numbers, drop-outs, and the evolving nature of the trial design (Figure 1A). The nature of OLE may introduce potential measurement and selection bias. To minimize bias, participants and assessors were blinded to the prior treatment assignment. We pre-specified a sensitivity analysis for a matched control group to account for potential baseline differences and selection bias. These sensitivity analyses support the main findings of reduced clinical onset and progression of the longest treated group. We also evaluated attrition and survivorship bias, noting very little attrition in the asymptomatic group from baseline double-blind to the OLE period (28% total attrition). As the hazard ratio may change over time, its interpretation should be restricted to the follow-up duration of the study. DIAD mutations result in early and substantial plaque formation. Given only partial reversal at the prior standard doses of gantenerumab used in SAD trials, we tripled the dose of gantenerumab in the OLE study. Even at this dose, amyloid plaques were not fully cleared in 70% of participants after a one year of dose titration and one year at maximum doses, though there was substantial progress toward amyloid removal with an acceptable safety profile. Whether even more effective amyloid removal would further increase clinical benefit remains an open question. The use of external and internal controls, the limited follow-up duration, and difference in the follow-up duration between treatment and control groups limit the conclusiveness of these observations, warranting additional follow-up. These limitations are mitigated by the large degree of amyloid plaque removal, the consistency between clinical and biological measures improving towards normal, and the large clinical effect size seen in the longest treated group.

Anti-amyloid therapy trials in presymptomatic populations at risk for developing AD, including the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia trial of crenezumab in individuals with *PSEN1* E280A mutation and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Phase 3 trial of solanezumab, have not demonstrated slowing of cognitive decline before. Amyloid removal measured by amyloid PET was minimal in each trial. Negative trial outcomes may be due to incorrect targets (e.g. soluble only species), inadequate doses or insufficient treatment duration (4 years for double-blind period vs. 8 years follow-up in this OLE). In this extended trial, we found clinical indicators of delayed progression in those treated for the longest with gantenerumab, which removed most amyloid plaques. To date, all trials in mutation carriers have predicted outcomes in late-onset SAD (see Supplemental Table 7), and so an open question is whether these findings will be replicated in

ongoing prevention trials of SAD that remove plaques.[17,18]

In conclusion, while further investigation and larger-scale trials are needed to confirm clinical effects, these results offer cautious optimism that disease modification in individuals at risk for AD may be possible. We launched the DIAN-TU Amyloid Removal Trial (NCT06384573) to continue following this cohort to determine the robustness of these findings and if this cohort continues to be protected from dementia onset. Furthermore, ongoing follow-up could enable the development of more accurate ARIA predictors, which is critical for improving participant management, by identifying high-risk participants and increasing the frequency of monitoring and dose adjustments. Continued follow-up of this unique DIAN-TU cohort exposed to long-term amyloid-plaque reducing monoclonal antibodies, other DIAN-TU cohorts, and the results of other ongoing prevention trials in SAD will be crucial in shaping the future direction of AD prevention efforts.

FIGURES AND TABLES

Figure 1. Trial profile and study populations. A. Gantenerumab/solanezumab double-blind and gantenerumab open-label extension arms of the DIAN-TU-001 prevention trial. B. Participants treated with gantenerumab in either the double-blind or OLE period (Any Gant) were compared to the main set control (internal placebo treated only and external matched controls from DIAN Observational (DIAN Obs) study. Baseline for this population was defined as double-blind baseline for original gantenerumab treated participants and OLE baseline for original placebo and solanezumab treated participants. C. Participants that were treated with gantenerumab for the longest duration in both the double-blind and OLE period (Longest Gant) and compared to the main set control or the extended control group (dashed box) which are defined as the main set controls plus the double-blind data and OLE baseline values for participants treated with placebo during the double-blind period who entered the OLE. Double-blind baseline was defined as the baseline for this population. D. Participants that were treated with gantenerumab in the OLE period (OLE Only Gant) and only their OLE period data were compared to the main set control. OLE baseline was defined as the baseline for this population.

Table 1. Demographics and baseline characteristics of the analysis populations for the gantenerumab open-label extension

	Overall		Baseline Asymptomatic				
	OLE only Gant baseline (n = 62)	Main set of control (n = 144)	Any Gant treated mITT (n = 53)	Longest Gant treated mITT (n = 22)	OLE only Gant baseline (n = 40)	Main set of control (n = 74)	Extended set of control (n = 86)
Age (years) (mean ± SD)	48.3 ± 8.03	41.7 ± 9.89	43.0 ± 8.07	43.1 ± 7.32	46.1 ± 7.20	37.24 ± 9.47	37.6 ± 9.11
Female (n (%))	35 (56)	81 (56)	28 (53)	11 (50)	24 (60)	46 (62)	55 (64)
Gene (n (%))							
APP	7 (11)	22 (15)	3 (6)	0 (0)	3 (7)	9 (12)	10 (12)
PSEN1	50 (81)	113 (78)	45 (85)	19 (86)	32 (80)	58 (78)	68 (79)
PSEN2	5 (8)	9 (6)	5 (9)	3 (14)	5 (13)	7 (9)	8 (9)
APOE ε4 (n (%))	17 (27)	43 (30)	17 (32)	4 (18)	10 (25)	18 (24)	21 (24)
EYO median (Q1, Q3)	0.33 (-3.62, 4.01)	-2.91 (-11.71, 2.14)	-5.86 (-9.03, -0.34)	-7.16 (-10.53, -5.14)	-2.84 (-5.71, 0.58)	-10.77 (-13.59, -4.17)	-9.61 (-13.39, -4.39)
CDR 0 (n (%))	40 (65)	74 (51)	53 (100)	22 (100)	40 (100)	74 (100)	86 (100)
CDR 0.5 (n (%))	10 (16)	54 (38)	0	0	0	0	0
CDR 1 (n (%))	10 (16)	16 (11)	0	0	0	0	0
CDR-SB median (Q1, Q3)	0 (0, 2.00)	0.50 (0, 2.50)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
FAS median (Q1, Q3)	0 (0, 1.11)	0 (0, 3.75)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Cognitive composite median (Q1, Q3)	0.45 (-0.13, 0.99)	0.07 (-0.49, 0.61)	0.67 (0.14, 1.04)	0.58 (0.14, 1.02)	0.78 (0.32, 1.12)	0.48 (0.15, 0.86)	0.50 (0.18, 0.85)
MMSE median (Q1, Q3)	29.0 (27.0, 30.0)	28.5 (25.0, 30.0)	30.0 (28.0, 30.0)	30.0 (29.0, 30.0)	30.0 (29.0, 30.0)	29.0 (29.0, 30.0)	29.0 (29.0, 30.0)
PiB-PET SUVR median (Q1, Q3)	2.3 (1.6, 3.4)	2.2 (1.5, 3.2)	2.0 (1.2, 2.7)	1.7 (1.5, 2.2)	1.9 (1.3, 2.6)	1.7 (1.1, 2.5)	1.7 (1.2, 2.5)
PiB-PET Centiloid median (Q1, Q3)	48 (19, 96)	52 (14, 90)	44 (10, 65)	26 (14, 48)	31 (10, 63)	26 (2, 59)	32 (7, 59)
Total dose (mg) median (Q1, Q3)	61.4K (39.5K, 101.4K)	0	62.4K (44.8K, 102.6K)	110.5K (90.3K, 122.2K)	68.6K (53.2K, 110.5K)	0	0

[a]For any grant treated mITT, double-blind baseline was used for prior gantenerumab treated participants and OLE baseline was used for prior placebo and solanezumab treated participants. For Longest Gant treated mITT, double-blind baseline was used. For OLE only Gant, OLE baseline was used. Any Gant=participants treated with gantenerumab in either the double-blind or OLE period, *APOE* ε4=presence of at least one ε4 allele of apolipoprotein E, *APP*=amyloid precursor protein, CDR=Clinical Dementia Rating, CDR-SB=Clinical Dementia Rating – Sum of Boxes, EYO=estimated years to symptom onset, FAS=Functional Assessment Scale,

Longest Gant=participants treated with gantenerumab in both the double-blind and OLE periods, mITT=modified intent-to-treat population, OLE only Gant=participants treated with gantenerumab in the OLE period, PiB-PET=[11]C-Pittsburgh compound-B positron emission tomography, *PSEN1*=presenilin-1, *PSEN2*=presenilin-2, SUVR=standardized uptake value ratio.

Figure 2. Primary and secondary biomarker outcomes

Estimated mean change from open-label extension (OLE) baseline (95% confidence intervals) for the treatment group using mixed model for repeated measures analyses for (a) the primary outcome of the OLE - brain amyloid burden measured by the average standardized uptake value ratio (SUVR) of cortical regions of interest (superior frontal, rostral middle frontal, superior temporal, middle temporal, lateral orbitofrontal, medial orbitofrontal and precuneus), assessed by ^{11}C-Pittsburgh compound-B positron emission tomography (PiB-PET), (b) cerebrospinal fluid (CSF) Aβ42/40, and (c) CSF phospho-tau181/non-phosphorylated tau. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$.

Table 2. Final Analysis Secondary outcomes. For cognitive composite, FAS and MMSE, positive difference in rate of change indicates positive treatment effect. For tau PET SUVR, negative difference in rate of change indicates positive treatment effect. For CentiMarker, negative change from baseline indicates positive treatment effect.

OLE only Gant mITT population at baseline	Gantenerumab/ control groups (n)	Group difference in rate of change (95% CI)	*P* value
OLE Cognitive Composite			
Asymptomatic	n=43 / n=73	0.04 (-0.12 to 0.20)	0.64
Symptomatic	n=20 / n=70	0.04 (-0.18 to 0.26)	0.75
Functional Assessment Scale			
Asymptomatic	n=43 / n=74	-0.06 (-0.46 to 0.33)	0.76
Symptomatic	n=22 / n=69	-1.21 (-2.63 to 0.20)	0.093
Mini-Mental State Examination			
Asymptomatic	n=43 / n=74	0.00 (-0.43, 0.44)	0.99
Symptomatic	n=22 / n=70	0.20 (-0.86, 1.25)	0.71
Tau-PET SUVR			
Asymptomatic	n=38 / n=5	-0.03 (-0.18 to 0.13)	0.74
Symptomatic	n=19 / n=7	0.19 (-0.28 to 0.66)	0.40

OLE only Gant treated population	Gantenerumab group (n)	Mean change from baseline (95% CI)	*P* value
Change from baseline to year 3 in CSF Amyloid-beta 1-42/1-40 (CentiMarker)	60	-42(-52, -31)	< 0.0001
Change from baseline to year 3 in CSF p-tau181/tau181 (CentiMarker)	60	-21 (-25, -17)	< 0.0001

Any Gant=participants treated with gantenerumab in either the double-blind or OLE period, CDR=Clinical Dementia Rating, CDR-SB=Clinical Dementia Rating – Sum of Boxes, CI=confidence interval, CSF=cerebrospinal fluid, Longest Gant=participants treated with gantenerumab in both the double-blind and OLE periods, mITT=modified intent-to-treat population, OLE only Gant=participants treated with gantenerumab in the OLE period, PiB-PET=[11]C-Pittsburgh compound-B positron emission tomography, p-tau181=phosphorylated tau at threonine 181, tau181=non-phosphorylated tau at threonine 181, SUVR=standardized uptake value ratio

For the Functional Assessment Scale, Tau-PET and CSF NfL, a negative difference indicates positive treatment effect. For the cognitive composite and MMSE (a component of the cognitive composite), a positive difference indicates positive treatment effect. For CSF Amyloid-beta 1-

42/1-40, a positive change from baseline indicates positive treatment effect. For CSF p-tau181/tau181, a negative change from baseline indicates positive treatment effect.

Table 3. Adverse Events by Treatment Group

Double-blind period			Open-label extension period		
	Shared placebo (N=40) n (%)	**Gantenerumab (N=52) n (%)**		**Gantenerumab (≥1020 mg Q2W; N=60) n (%)**	**Gantenerumab (all doses; N=73) n (%)**
Injection site reactions	18 (45)	47 (90)	Infusion reactions	47 (78)	51 (70)
Amyloid related imaging abnormalities (ARIA)					
ARIA-E	1 (3)	10 (19)		17 (28)	22 (30)
ARIA-H					
Microhemorrhage	4 (10)	13 (25)		24 (40)	34 (47)
Superficial siderosis	0 (0)	2 (4)		3 (5)	5 (7)

ARIA=amyloid-related imaging abnormalities, ARIA-E=amyloid-related imaging abnormalities with edema, ARIA-H=amyloid-related imaging abnormalities with haemosiderosis/microhemorrhages, LP=lumbar puncture, Q2W=every 2 weeks

Figure 3. Probability of progression in CDR global and CDR-SB estimated from the Cox proportional hazards model. Lower probability of progression in treatment group and hazard ratio indicates higher reduction in the risk of progression and therefore better treatment effect. A and B. Any Gant mITT population baseline asymptomatic group vs main set of control; C and D. Longest Gant mITT population baseline asymptomatic group vs main set of control; E and F. Longest Gant mITT population baseline asymptomatic group vs extended set of control; G and H. OLE only Gant mITT population baseline asymptomatic group vs main set of control.

Contributors

R.J.B., Y.L., E.M.M., J.J.L.G., D.B.C., S.L.M., A.M.S., G.W., C.S., T.L.S.B., B.A.G., L.I., G.K., M.B., R.S.D., A.A., P.D., G.A.K., J.H., A.J.A., R.J.P, C.C., A.R., C.X. designed the study and wrote the study protocol. T.B., J.W., A.B., P.F., C.H., L.K., A.A.G., J.C.M., D.M.H. provided additional input to the study design. R.J.B., E.M.M., D.B.C., J.J.L.G, S.L.M. and A.M.S. coordinated the trial. B.J.S., C.M., D.W., S.B.B., E.D.R., C.H.V.D., R.S., W.S.B., S.G., D.R.G., C.L.M., S.J., G.R.H., M.M., B.D, J.P., J.K., L.H. recruited and treated the patients and collected the data. G.W., Y.L., C.X., T.B., and P.D. performed the statistical analysis. S.L.M. and A.M.S. were responsible for central and local data management. L.I. performed the analysis of the CSF biomarkers data. C.R.J., T.L.S.B. and B.A.G. performed the processing and analysis of the neuroimaging data. C.C. and A.R. were responsible for the sequencing and genetic analysis. Every author contributed to the initial draft of the manuscript and agreed on submission for publication. All authors interpreted the data, reviewed the manuscript and approved the final version.

Declaration of Interests

R.J.B. is Director of DIAN–TU and Principal Investigator of DIAN–TU-001. He receives research support from the NIA of the NIH, DIAN–TU trial pharmaceutical partner (Hoffman-La Roche Ltd), Alzheimer's Association, GHR Foundation, Anonymous Organization, DIAN–TU Pharma Consortium (Active: AbbVie, Biogen, BMS, Eisai, Eli Lilly & Co., Ionis, Janssen, Prothena, Roche/Genentech. Previous: Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, United Neuroscience). He has been a scientific advisor for NAPA Advisory Council Biogen, F. Hoffman-La Roche/Genentech Ltd, UK Dementia Research Institute at University College London and Stanford University. He has been an invited speaker for Alzheimer's Association, Duke Margolis Alzheimer's Roundtable, BrightFocus Foundation, Tau Consortium, NAPA Advisory Council on Alzheimer's Research, CTAD, FBRI, Beeson, Adler Symposium and Fondazione Prada. R.J.B. and D.M.H. are co-founders of C2N Diagnostics and receive income from C2N Diagnostics for serving on the scientific advisory board. Washington University has equity ownership interest in C2N Diagnostics.   R.J.B. and D.M.H. are co-inventors of the stable isotope labeling kinetics and blood plasma assay technology licensed by Washington University to C2N Diagnostics. Through these relationships, Washington University, R.J.B. and D.M.H. are entitled to receive royalties and/or equity from the license agreement with C2N. E.M.M. is the Co-Director of the DIAN-TU. He receives research support from the NIA of the NIH, DIAN-TU-002 Trial pharmaceutical partner (Eli Lilly and Company), Alzheimer's Association, and GHR Foundation. He has been a consultant to Astra Zeneca, F. Hoffman-LaRoche Ltd, Sanofi and Merck. He has been an invited speaker for Alzheimer's Association, Projects in Knowledge (Kaplan), Neurology Live, American Academy of Neurology and University of Maryland. He has received support to attend meetings at Fondation Alzheimer, McGill University, University of Massachusetts and Australian and New Zealand Association of Neurologists. He reports serving on a Data Safety Committee for Alnylam and Alector. J.J.G.L. is Co-Medical Director of DIAN–TU. He receives research support from the NIA of the NIH and the Alzheimer's Association. D.B.C. is Co-Medical Director of DIAN–TU. He receives royalties from Wolters Kluwer. He serves as scientific consultant to F. Hoffmann-La Roche Ltd/Genentech, Wave Life Sciences, Excision BioTherapeutics, Atara Biotherapeutics Inc, Sanofi Genzyme, Cellevolve Bio, Inc., Seagen Inc. and ICON (Teva). He has carried out legal consulting for Lewis, Thomason, King, Krieg and Waldrop (PML) and Loughren, Loughren, Loughren Powell Gilbert LLP. He serves on the Data Safety Monitoring Board for Wave Life Sciences, Excision Biotherapeutics Inc, Sanofi

Genzyme, Atara Biotherapeutics Inc, Cellevolve Bio, Inc. G.W. serves as a consultant for Alector and Pharmapace. He serves on the data safety monitoring board for Eli Lilly and Co. T.L.S.B. has investigator-initiated research funding from the NIH, Avid Radiopharmaceuticals, Siemens and Hyperfine. She is a consultant to Biogen, Eisai, Eli Lilly, Bristol Myers Squibb and Janssen and Janssen. She is on the Speaker's Bureau for Medscape and Peerview. She serves on the data safety monitoring board for Eisai and Siemens. She provides unpaid leadership to the ASNR Alzheimer's, RSNA Quantitative Imaging Committee, American College of Radiology/ALZ NET and NIH CNN Study Section Chair. B.A.G. receives research support from the NIA of the NIH. G.K., M.B.K., R.S.D., P.D., G.A.K., T.B., A.B., P.F., C.H. and L.K. are employees of F. Hoffmann La Roche. J.H. is a consultant to Parabon Nanolabs, Prothena and AlzPath. He serves on the data safety monitoring board for Caring Bridge and Wall-E. A.J.A. receives research support from the NIA of the NIH and he is a consultant to Albert Einstein College of Medicine. R.J.P. and A.E.R. receives research support from the NIA of the NIH. C.C. receives research support from the NIA of the NIH and the Michael J. Fox Foundation. He is a consultant for Circular Genomics and Alector. C.X. receives research support from the NIH and he is a consultant for Diadem. He serves of the FDA Advisory Committee on Imaging Medical Products. A.A.G. is a consultant for Genentech and Muna Therapeutics. J.C.M. is the Friedman Distinguished Professor of Neurology, Director of the Charles F. and Joanne Knight Alzheimer's Disease Research Center, Associate Director of DIAN and Founding Principal Investigator of DIAN. His research is funded by NIH and his is a consultant for Barcelona Brain Research Center and the Native Alzheimer Disease-related resource center in Minority Aging Research. He has been an invited speaker for the AAIM Longer Life Foundation and the International Brain Health Symposium. He serves on the data safety monitoring board for Cure Alzheimer's Fund and LEADS Advisory Board. D.M.H. receives research support from the NIH. He serves as a consultant for Genentech, Denali, and Cajal Neurosciences. He is a co-inventor of the stable isotope labeling kinetics and blood plasma assay technology licensed by Washington University to C2N Diagnostics. Through these relationships, Washington University, D.M.H. is entitled to receive royalties and/or equity from the license agreement with C2N. B.J.S. receives research clinical trial support from NIH, Biogen, Eisai, Eli Lilly, F. Hoffmann La Roche, Janssen and Alzheimer's Association. She is a consultant for Eisai, Roche and Altheneum, Slingshot. She received honoraria from the AAN and the ANA. She receives royalties from Elsevier. C.M. receives research support from Biogen and the NIHR. She is a consultant for Eli Lilly, Biogen and Eisai. She has received honoraria from Eli Lilly and Eisai. She serves on the data safety monitoring board for Eli Lilly, Novartis and F. Hoffman La Roche/Genentech, Eisai and Immunobrain. E.R. receives research support from the NIH, ADDF and Bluefield Projectx. He receives royalties from Genentech. He is a consultant for AGTC. He serves on the data safety monitoring board for Eli Lilly and serves as fiduciary for the Society for Neuroscience. C.H.V.D. has served as a consultant for F. Hoffmann-La Roche Ltd, Cervel, Ono and Eisai and received grant support for clinical trials from F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Biogen, Genetech, Janssen, Eisaiand Cerevel. R.S.V. receives grant support from ISCIII. She is a consultant for UCB, Pfizer and Lilly. She has received honoraria from Neuraxpharm, and Roche. She serves on the data safety monitoring board of Wave Pharmaceuticals. W.S.B. received financial support from Roche to attend an educational meeting about management of Alzheimer's disease. S.G. received honoraria from Lundbeck and Biogen, and travel support from TauRx. He serves on the data safety monitoring board for Alzheon, AmyriAD, Eisai, ENIGMA, Lilly, Okutsa, Nordisk, TauRx and AbbVie. He serves on the board of the Francis Foundation. D.R.G. is a consultant for Eisai, Biogen and Fujirebio, Inc. He has received honoraria from GE Healthcare and he serves on the data safety committee for

Artery Therapeutics, Inc. G.S.H. receives research support from the NIH, CIHR, Biogen, Roche, Cassava and Eisai. He is a consultant for Biogen, Roche, Novonordisk, Eisai and Eli Lilly. He also serves unpaid as the president of the Consortium of Canadian Centres for Clinical Cognitive Research. M.M. receives research support from the Ontario Brain Institute, Women's Brain Health Initiative, Brain Canada, Roche, Canadian Institutes of Health Research, Alector and Weston Brain Institute. He reports receiving royalties from Henry Stewart Talks. He is a consultant for Eli Lilly, Alector, Biogen, Wave Life Sciences, Eisai and Novo-Nordisk. He has received honoraria from MINT Memory Clinics and ECHO Dementia Series. He serves unpaid on committees for Alzheimer Society Canada and Parkinson Canada. B.D. is a consultant for Fondation Recherche Alzheimer, Qynapse and Eisai and is an unpaid board member for the Foundation Claude Pompidou. J.P. serves on the data safety committee for Biogen and Borhinger. L.S.H. receives research support from the NIH, Acumen, Alector, Biogen, Cognition, EIP, Eisai, Ferrer, Genentech, Janssen/J&J, Roche, Transposon, UCB and Vaccinex. He is a consultant for Biogen, Corium, Eisai, New Amsterdam and Roche. He has received honoraria from Medscape and serves on the data safety committee for Cortexyme and Eli Lilly. J.C. receives research support from the NIH and the Doris Duke Charitable Foundation. He is a consultant for MedaCorp. G.D. receives research support from NIH, Alzheimer's Association, Chan Zuckerberg Association. He is a consultant for Parabon Nanolabs, Arialys Therapeutics and Ionis. He has received honoraria from PeerView Media, Eli Lilly, DynaMed and Continuing Medical Education, Inc. He served as an unpaid clinical director for Anti-NMDA Receptor Encephalitis Foundation. He reports owning stocks in ANI Pharmaceuticals and Parabon Nanolabs. N.C.F. is a consultant for Eisai, F. Hoffmann La Roche, Eli Lilly, Ionis, Biogen and Siemens. He has received honoraria from F. Hoffmann La Roche and serves on the Alzheimer's Association Research Strategy Council. A.I.L. receives research support from the NIH. He reports royalties from Linus Health and Emtherapro. He is a consultant for MEPSGEN and Emtherapro. He serves on the data safety monitoring board for NextSense, Karuna and Cognito Therapeutics. He reports stock relationships with Emtherapro and NextSense. T.I. received research support from AMED JP23dk02027066. He is a consultant for Eli Lilly and Novo Nordisk. He received honoraria from Eisa, Fuji Rubio and Eli Lilly. J.L. receives research support from the German Center for Neurodegenerative Diseases. He is a consultant for Eisai and Biogen. He has received honoraria from Bayer Vital, Biogen, Eisai, Teva, Roche, Esteve and Zambon. He serves on the data safety committee for Axon Neuroscience and he is an unpaid board member for ERN-RND Management, ERN-RND Atypical Parkinson Disease Coordinator and the Deutsches Netzwerk Gedachtnisambulanzen. F.L. receives research support from the NIH, Banner Institute and Roche. He is a consultant for Biogen and Technoquimicas. He has received honoraria from Tecnofarma. P.R.N. is a consultant for Novodisk, Eli Lilly and Biogen. P.R.S. receives research support from the NIH, NHMRC, MRFF and Roth Charitable Foundation. He is a consultant for Outside Opinion Pty Ltd, Moira Clay Consulting Pty Ltd and Neuroscience Research Australia. He is the director of the Australian Dementia Network Ltd, Neuroscience Research Australia, Health Science Alliance, Schizophrenia Research Institute, StandingTall Pty Ltd and Australian Association of Medical Research Institutes. He is president of the Australasian Neuroscience Society. L.T. participates on the data safety monitoring board of Denali and has received research support from the NIH and Alzheimer's Association. Y.L., S.L.M., A.M.S., C.S., L.I., D.W., S.B.B., C.L.M., S.J., J.K., C.R.J., A.D., R.A., B.G., E.D.H., M.J., J.H.L., J.H.R. and A.L.S. do not declare any competing interests. The funders of the study had no role in the collection, analysis or interpretation of the data, the writing of the report or in the decision to submit the paper for publication.

Correspondence and requests for materials should be addressed to R.J.B.

Data Sharing

Data access to the DIAN–TU trial data will follow the policies of the DIAN–TU data access policy (https://dian.wustl.edu/wp-content/uploads/2021/02/DIANTUResourceSharePublAuthorPolicy_Ver1.0_12Jan2021.pdf), which complies with the guidelines established by the Collaboration for Alzheimer's Prevention. Patient-related data not included in the paper were generated as part of a clinical trial and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a data/material sharing agreement. Requests to access the DIAN–TU-001 trial data can be made at https://dian.wustl.edu/our-research/for-investigators/diantu-investigator-resources/. All code for data cleaning and analysis associated with the current submission is available upon request to the corresponding author and is provided as part of the replication package.

Acknowledgements

Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers U01AG042791, U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), R1AG046179, R01AG053267, R01AG053267-S1, R01AG053267-S2. The research for the DIAN-TU-001 gantenerumab open label extension was supported by the Alzheimer's Association and F. Hoffman-LaRoche Ltd. The research for the DIAN-TU-001 trial, solanezumab and gantenerumab drug arms, was also supported by the Alzheimer's Association, Eli Lilly and Company, F. Hoffman-LaRoche Ltd., Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company), GHR Foundation, an anonymous organization, Cerveau Technologies, Cogstate, and Signant. The DIAN-TU has received funding from the DIAN-TU Pharma Consortium. We acknowledge the altruism of the participants and their families and contributions of the DIAN, DIAN Expanded Registry, and DIAN-TU research and support staff at each of the participating sites (see DIAN-TU Study Team) for their contributions to this study.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Statistical data analysis support was provided by Daniel Yen.

REFERENCES

1.   Hardy JA, Higgins GA. Alzheimer's Disease: The Amyloid Cascade Hypothesis | Science. Science. 1992;256(5054):184–5.

2.   Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016 Jun;8(6):595–608.

3.   Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022;9(2):197–210.

4.   van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023 Jan 5;388(1):9–21.

5.   Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):512–27.

6.   Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991 Feb 21;349(6311):704–6.

7.   Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995 Jun 29;375(6534):754–60.

8.   Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995 Aug 18;269(5226):973–7.

9.   Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795–804.

10.   Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul;27(7):1187–96.

11.   Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, et al. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. 2024 Apr 29;e240991.

12.   Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16;389(20):1862–76.

13.   PRENTICE RL, WILLIAMS BJ, PETERSON AV. On the regression analysis of multivariate failure time data. Biometrika. 1981 Aug 1;68(2):373–9.

14.   Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining

imaging biomarker cut-points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017 Mar;13(3):205–16.

15. Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, et al. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Annals of Neurology. 2022;92(5):729–44.

16. Joseph-Mathurin N, Wang G, Kantarci K, Jack CR, McDade E, Hassenstab J, et al. Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology. 2021 Mar 23;96(12):e1632–45.

17. Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, et al. The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022 Aug 15;19(4):1227.

18. Eli Lilly and Company. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease [Internet]. clinicaltrials.gov; 2024 Oct [cited 2024 Oct 22]. Report No.: NCT05026866. Available from: https://clinicaltrials.gov/study/NCT05026866

19. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15;83(3):253–60.

20. McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018 Oct 2;91(14):e1295–306.

21. Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023 Nov 1;146(11):4414–24.

22. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume correction in quantitative amyloid imaging. NeuroImage. 2015 Feb 15;107:55–64.

23. Barthélemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. Nat Aging. 2023;3(4):391–401.

24. Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017 Aug;13(8):841–9.

25. Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2016 Jan;73(1):60–7.